


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A compound of formula I,




(I)

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound according to claim 1, wherein the compound is 8-[(2,6-dimethylbenzyl)amino]-N-[(2S)-2-hydroxypropyl]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt.


3. (Currently amended) A process for the preparation of a compound according to claims 1 or 2, comprising the steps of:

a) treating a compound of Formula II,




wherein R¹ represents a C₁-C₆-alkoxy group or -NH₂,

with an aqueous acid or base under standard conditions, to form a compound of Formula III; and



b) reacting the compound of Formula III with a compound of Formula IV,



in the presence of o-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) a coupling reagent in an inert solvent under standard conditions, to give a compound of

Formula I, and optionally converting the compound of Formula I to a pharmaceutically acceptable salt.


4. (Canceled)

5. (Previously presented) A pharmaceutical formulation comprising the compound according to claim 1 or 2 as active ingredient in combination with one or more pharmaceutically acceptable diluents or carriers.

6. (Canceled)

7. (Previously presented) A method for the treatment or inhibition of a gastric acid related disease, gastrointestinal inflammatory disease, heartburn, symptomatic GERD, erosive esophagitis, peptic ulcer disease, regurgitation, acid reflux disease, or nausea in a patient, the method comprising administering an effective amount of a compound according to claim 1 or 2 to the patient in need thereof.

8. (Previously presented) A compound of Formula III,



(III).